The importance of early identification of infusion-related reactions to monoclonal antibodies

References

• Lushova A, Biazrova M, Prilipov A, Sadykova G, Kopylov T, Filatov A. Next-generation techniques for discovering human monoclonal antibodies. Mol Biol. 2017;51(6):782–787. doi:10.1134/S0026893317060103
   PubMed Web of Science ®Google Scholar
• Machado NP, Tèllez GA, Castaño JC. Anticuerpos monoclonales: desarrollo físico y perspectivas terapéuticas [Monoclonal antibodies: physical development and therapeutic perspectives]. Infectio. 2006;10(3):186–197.
   Google Scholar
• Cui Y, Cui P, Chen B, Li S, Guan H. Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Dev Ind Pharm. 2017;43(4):519–530. doi:10.1080/03639045.2017.127876828049357
   PubMed Web of Science ®Google Scholar
• Merino AG. Anticuerpos monoclonales. aspectos básicos. [Monoclonal antibodies. Basic aspects]. Neurología. 2011;26(5):301–306. doi:10.1016/j.nrl.2010.10.00521193249
   PubMed Web of Science ®Google Scholar
• Brennan FR, Morton LD, Spindeldreher S, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. mAbs. 2010;2(3):233–255. doi:10.4161/mabs.2.3.1178220421713
   PubMed Web of Science ®Google Scholar
• Stanulovic V, Zelko R, Kerpel-Fronius S. Predictability of serious adverse reaction. Int J Clin Pharmacol Ther. 2011;49(3):185–190. doi:10.5414/cp20149721329620
   PubMed Web of Science ®Google Scholar
• Stanulovic V, Kadlecova P, Zelko R, Kerpel-Fronius S. Earlier identification of risks: cumulative probability analysis of time to safety alerts for therapeutic monoclonal antibodies. Int J Clin Pharmacol Ther. 2015;53(7):499–503. doi:10.5414/CP20228325997549
   PubMed Web of Science ®Google Scholar
• Cáceres MC, Durán-Gómez N, Guerrero-Martín J, Pérez Civantos DV, Carreto-Lemus MA, Postigo-Mota S. Interés para la enfermera de los nuevos anticuerpos monoclonales. una revolución terapéutica. Revista Rol De Enfermera. 2017;40(7–8):524–530.
   Google Scholar
• Namey M, Halper J, O’leary S, Beavin J, Bishop C. Best practices in multiple sclerosis: infusion reactions versus hypersensitivity associated with biologic therapies. J Infus Nurs. 2010;33(2):98–111. doi:10.1097/NAN.0b013e3181cfd36d20228647
   PubMedGoogle Scholar
• Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14(2):E10. doi:10.1188/10.CJON.E10-E2120350882
   PubMedGoogle Scholar
• Korycka-Wołowiec A, Wołowiec D, Robak T. The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Expert Opin Drug Saf. 2017;16(2):185–201. doi:10.1080/14740338.2017.126438727880061
   PubMed Web of Science ®Google Scholar
• Cima (aemps); 2018 Available from: https://cima.aemps.es/cima/publico/home.html.
   Google Scholar
• Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunol. 2015;4(7):e39. doi:10.1038/cti.2015.14
   PubMedGoogle Scholar
• Kang SP, Saif MW. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer – identification, prevention, and management. J Support Oncol. 2007;5(9):451–457.18019853
   PubMedGoogle Scholar
• Calogiuri G, Ventura MT, Mason L, et al. Hypersensitivity reactions to last generation chimeric, umanized and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des. 2008;14(27):2883–2891.18991706
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2019 Available from: http://www.whocc.no/atc_ddd_index/.
   Google Scholar
• Isabwe GAC, Neuer MG, de Las Vecillas Sanchez L, Lynch D, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142(1):170. e2. doi:10.1016/j.jaci.2018.02.018
   PubMed Web of Science ®Google Scholar
• Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259–273. doi:10.1016/j.anai.2010.08.00220934625
   PubMed Web of Science ®Google Scholar
• Puig L, Sáez E, Lozano MJ, et al. Reacciones a la infusión de infliximab en pacientes dermatológicos. [reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol]. Actas Dermo-Sifiliográficas. 2009;100(2):103–112.19445874
   PubMedGoogle Scholar
• Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol. 2003;98(6):1315–1324. doi:10.1111/j.1572-0241.2003.07457.x12818276
   PubMed Web of Science ®Google Scholar
• Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7(1):55–63. doi:10.1586/eci.10.9021162650
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose. N Engl J Med. 2008;358(11):1109–1117. doi:10.1056/NEJMoa07494318337601
   PubMed Web of Science ®Google Scholar
• Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit Rev Ther Drug Carrier Syst. 2001;18(6):567–606.11789676
   PubMed Web of Science ®Google Scholar
• Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216(2):106–121. doi:10.1016/j.tox.2005.07.02316140450
   PubMed Web of Science ®Google Scholar
• Fülöp T, Mészáros T, Kozma G, Szebeni J, Józsi M. Infusion reactions associated with the medical application of monoclonal antibodies: the role of complement activation and possibility of inhibition by factor H. Antibodies. 2018;7(1):14. doi:10.3390/antib7010014
   Web of Science ®Google Scholar
• Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89. doi:10.1186/s13054-017-1686-128407743
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi:10.1186/s40425-018-0343-929907163
   PubMed Web of Science ®Google Scholar
• Cardona V, Cabañes N, Chivato T, De la Hoz B, Fernández Rivas M, Gangoiti Goikoetxea I. Guía de actuación en anafilaxia: Galaxia 2016 [Anaphylaxis Action Guide: Galaxia]. Available from: https://www.aepnaa.org/recursos/publicaciones-archivos/5851f6dd835b9ffc3f32220233dc3eca.pdf. Spanish.
   Google Scholar
• US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. national institutes of health, national cancer institute; 2017.
   Google Scholar
• Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13(6):725–732. doi:10.1634/theoncologist.2008-001218586928
   PubMed Web of Science ®Google Scholar
• Dotson E, Crawford B, Phillips G, Jones J. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow. Support Care Cancer. 2016;24(3):1125–1129. doi:10.1007/s00520-015-2869-426268782
   PubMed Web of Science ®Google Scholar
• Ikegawa K, Suzuki S, Nomura H, et al. Retrospective analysis of premedication, glucocorticosteroids, and H1-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer. J Int Med Res. 2017;45(4):0300060517713531.
   Web of Science ®Google Scholar
• Thompson LM, Eckmann K, Boster BL, et al. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist. 2014;19(3):228–234. doi:10.1634/theoncologist.2013-028624536030
   PubMed Web of Science ®Google Scholar
• Snowden A, Hayden I, Dixon J, Gregory G. Prevention and management of obinutuzumab‐associated toxicities: Australian experience. Int J Nurs Pract. 2015;21(S3):15–27. doi:10.1111/ijn.1241226681665
   PubMed Web of Science ®Google Scholar
• Bartoli F, Bruni C, Cometi L, et al. Premedication prevents infusion reactions and improves retention rate during infliximab treatment. Clin Rheumatol. 2016;35(11):2841–2845. doi:10.1007/s10067-016-3351-527436188
   PubMed Web of Science ®Google Scholar
• Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol. 2016;4(3):497–504. doi:10.1016/j.jaip.2015.12.019
   Web of Science ®Google Scholar
• Brennan PJ, Bouza TR, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259–1266. doi:10.1016/j.jaci.2009.09.00919910036
   PubMed Web of Science ®Google Scholar
• Bonamichi-Santos R, Castells M. Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies. Clin Rev Allergy Immunol. 2018;54(3):375–385. doi:10.1007/s12016-016-8556-527277133
   PubMed Web of Science ®Google Scholar
• Guidelines for preparing core clinical-safety information on drugs second edition – report of CIOMS working groups III and V • COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES; 1999 Available from: https://cioms.ch/shop/product/guidelines-preparing-core-clinical-safety-information-drugs-second-edition-report-cioms-working-groups-iii-v/. Accessed 510, 2019.
   Google Scholar